Prognostic value of histological type in stage IV ovarian carcinoma: A retrospective analysis of 223 patients

British Journal of Cancer

Volumn 112, Issue 8, 2015, Pages 1376-1383

  Mizuno, M ^a   Kajiyama, H ^a   Shibata, K ^a   Mizuno, K ^b   Kawai, M ^c   Nagasaka, T ^d   Kikkawa, F ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^d NAGOYA UNIVERSITY   (Japan)

Author keywords

clear cell carcinoma; epithelial ovarian cancer; prognostic factors; serous adenocarcinoma; stage IV

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; ENDOMETRIUM TUMOR; FEMALE; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LONG TERM SURVIVAL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TASK PERFORMANCE; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84928208506     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.97     Document Type: Article

References (31)

1. Classification and staging of malignant tumours in the female pelvis (1971) Acta Obstet Gynecol Scand 50(1): 1-7.
2. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y, Kodama S, Yamamoto K, Sato S (2001) Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 81(3): 398-403.
3. Baak JP, Wisse-Brekelmans EC, Langley FA, Talerman A, Delemarre JF (1986) Morphometric data to FIGO stage and histological type and grade for prognosis of ovarian tumours. J Clin Pathol 39(12): 1340-1346.
4. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA (2010) Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116(6): 1462-1468.
5. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72(3): 278-287.
6. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5): 1248-1259.
7. Brun JL, Feyler A, Chene G, Saurel J, Brun G, Hocke C (2000) Long-term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol 78(1): 21-27.
8. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109(3): 370-376.
9. Chereau E, Ballester M, Selle F, Cortez A, Pomel C, Darai E, Rouzier R (2009) Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. BJOG 116(8): 1062-1068.
10. Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB (2005) Does aggressive surgery only benefit patients with less advanced ovarian cancer Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol 23(34): 8802-8811.
11. Curtin JP, Malik R, Venkatraman ES, Barakat RR, Hoskins WJ (1997) Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64(1): 9-12.
12. Elstrand MB, Sandstad B, Oksefjell H, Davidson B, Trope CG (2012) Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective. Acta Obstet Gynecol Scand 91(3): 308-317.
13. Goodman HM, Harlow BL, Sheets EE, Muto MG, Brooks S, StellerM, Knapp RC, Berkowitz RS (1992) The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 46(3): 367-371.
14. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, Shepherd JH, Ind T, Bridges J, Harrington K, Kaye SB, Gore ME (2004) Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 22(6): 1040-1044.
15. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE (2007) Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105(1): 211-217.
16. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007, CA 57(1): 43-66.
17. Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Sekiya R, Niimi K, Mitsui H, Yamamoto E, Kawai M, Nagasaka T, Kikkawa F (2014) Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology. Journal Gynecol Oncol 25(1): 43-50.
18. Liu PC, Benjamin I, Morgan MA, King SA, Mikuta JJ, Rubin SC (1997) Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 64(1): 4-8.
19. Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D (2012) Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective french multicentric study. Int J Gynecol Cancer 22(8): 1337-1343.
20. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1): 1-6.
21. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, Nagasaka T, Nomura S (2006) Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol 94(2): 138-143.
22. Munkarah AR, Hallum III AV, Morris M, Burke TW, Levenback C, Atkinson EN, Wharton JT, Gershenson DM (1997) Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 64(1): 13-17.
23. Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta 2nd DM, Horowitz NS, del Carmen MG, Schorge JO (2012) Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol 19(3): 959-965.
24. Sobin LH, Gospodarowicz, Wittekind C (2009) TNM Classification of Malignant Tumours. 7th Edition Wiley-Blackwell: Chichester, UK.
25. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K (2000) Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88(11): 2584-2589.
26. Tavassoli FA, Devilee P (2003) Tumours of breast and female genital organs. IARC Press Pathology & Genetics: Lyon. 117-145.
27. Trimble E, Valmonte CM, Cheson BD (2000) Clinical trials referral resource. Current clinical trials in epithelial ovarian cancer. Oncology 14(5): 683-684, 687-8 passim.
28. Trope CG, Elstrand MB, Sandstad B, Davidson B, Oksefjell H (2012) Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV Eur J Cancer 48(14): 2146-2154.
29. Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS. European Organisation for RTreatment of Cancer-Gynaecological Cancer GGroup NCT (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 363(10): 943-953.
30. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17(6): 1642-1648.
31. Winter III WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 26(1): 83-89.